%A Zhang Baihong, Yue Hongyun %T Advances of next-generation immune checkpoint blockade %0 Journal Article %D 2018 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2018.04.012 %P 238-240 %V 45 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10439.shtml} %8 2018-04-08 %X Immune checkpoint blockades can induce long lasting responses but only in a fraction of patients owing to deficient of antibody as well as the neglect of immune suppressive cells. Nextgeneration immune checkpoint blockades, including FcγR-binding anti-programmed cell death-1 (PD-1）/PD ligand 1 (PD-L1) antibodies, coinhibitors of immune checkpoint, small-molecule modulators and antibody-drugs conjugated with PD-1/PD-L1, will overcome the deficiencies of current antiPD-1/PD-L1 antibodies and will become the direction of immunotherapy in the future.